Search results
HanxBio announces the publication of a research paper in Scientific Reports on preclinical...
FOX 4 Kansas City· 2 days agoHanxBio today announced that it has published a research article titled "Narazaciclib, a novel...
Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
Seeking Alpha· 7 days agoMoleculin Biotech's Annamycin receives Orphan Drug Designation from the European Medicines Agency for AML treatment, expanding its potential market reach.
Why Bio-Path Stock Is Soaring - Bio-Path Hldgs (NASDAQ:BPTH)
Benzinga· 7 days agoBio-Path said BP1002 may overcome and prevent some of the mechanisms of resistance that affect...
Promising Treatment Approach for Aggressive Leukemia Identified
Technology Networks· 6 days agoScientists have uncovered a promising treatment strategy for an aggressive type of leukaemia –...
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 3 days agoFood and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 14 hours agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
...Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute ...
Morningstar· 7 days ago“We are delighted to safely progress through the second, higher dose cohort to reach an important...with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study ...
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute ...
NBC 17 Raleigh· 7 days ago– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects ...
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Market Watch· 3 days agoThe San Diego-based biopharmaceutical company said the U.S. Food and Drug Administration had granted ziftomenib the status as a potential treatment for relapsed/refractory ...
Critical Survey: Coeptis Therapeutics (COEP) versus The Competition
ETF DAILY NEWS· 6 hours agoCoeptis Therapeutics (NASDAQ:COEP – Get Free Report) is one of 289 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We ...